Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800
investors@cymabay.com

Recent News

14Oct

CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference

1Oct

CymaBay Therapeutics Announces Presentations at The Liver MeetingĀ® 2019

30Sep

CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Upcoming Event

Oct 21 2019 9:00 am ET

H.C. Wainwright 3rd Annual NASH Investor Conference

October 21, 2019 at 9:00 am ET

New York City

Q2 2019 Quarterly Results